These findings not only indicate that bilirubin is a critical microenvironmental factor that negatively affects the efficacy of vemurafenib in patients with BRAF mutant, but also suggest that the melanoma patients with jaundice may reduce the efficacy of vemurafenib and predict poor prognosis. The gene discussed is BRAF; the disease is melanoma.